Recent exposure to several serotonergic medications followed by agitation, autonomic instability, hyperthermia, diarrhea, hyperreflexia, and clonus strongly indicates serotonin toxicity. Clonus is particularly important diagnostically.

Why the Other Options Are Incorrect

• A. Neuroleptic malignant syndrome: Usually causes slower-onset lead-pipe rigidity and reduced reflexes after dopamine blockade.
• C. Malignant hyperthermia: Usually occurs during or shortly after exposure to triggering anesthetic agents.
• D. Anticholinergic toxicity: Causes dry skin, urinary retention, reduced bowel sounds, and usually no clonus.
• E. Meningitis: May cause fever and confusion but does not explain the medication exposure, clonus, and hyperreflexia.

Clinical safety point Do not diagnose anxiety or panic disorder in a patient with objective clonus, hyperreflexia, hyperthermia, and serotonergic medication exposure

All contributing serotonergic agents should be stopped. Moderate or severe toxicity requires emergency treatment with airway and cardiovascular support, intravenous fluids, benzodiazepines for agitation and muscle activity, active cooling, and monitoring for complications.

Why the Other Options Are Incorrect

• A: Continuing any contributing serotonergic medication can worsen toxicity.
• C: Dopamine-blocking medication may complicate temperature regulation and is not the preferred initial treatment.
• D: Antipyretics do not adequately treat hyperthermia generated by sustained muscle activity.
• E: Exercise would increase muscular heat production.

Clinical safety point Do not diagnose anxiety or panic disorder in a patient with objective clonus, hyperreflexia, hyperthermia, and serotonergic medication exposure

Neuromuscular excitation—especially spontaneous, ocular, or inducible clonus with hyperreflexia—is characteristic of serotonin toxicity. Neuroleptic malignant syndrome more often produces generalized lead-pipe rigidity and normal or reduced reflexes.

Why the other options are less appropriate

• A. Altered mental status: is less consistent with the full clinical context and is not the single best answer.
• B. Fever: is less consistent with the full clinical context and is not the single best answer.
• D. Tachycardia: is less consistent with the full clinical context and is not the single best answer.
• E. Elevated creatine kinase: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not diagnose anxiety or panic disorder in a patient with objective clonus, hyperreflexia, hyperthermia, and serotonergic medication exposure

Cyproheptadine is an oral serotonin antagonist that may be considered for persistent moderate or severe serotonin toxicity. Supportive care, sedation, cooling, and management of airway and circulation remain the primary treatments.

Why the other options are less appropriate

• A. Atropine: is less consistent with the full clinical context and is not the single best answer.
• B. Levodopa: is less consistent with the full clinical context and is not the single best answer.
• C. Naloxone: is less consistent with the full clinical context and is not the single best answer.
• D. Flumazenil: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not diagnose anxiety or panic disorder in a patient with objective clonus, hyperreflexia, hyperthermia, and serotonergic medication exposure

Recent escalation of a dopamine-blocking medication followed by severe rigidity, hyperthermia, altered mental status, autonomic instability, and marked CK elevation indicates neuroleptic malignant syndrome.

Why the Other Options Are Incorrect

• A. Serotonin syndrome: More commonly produces rapid-onset clonus, hyperreflexia, tremor, and gastrointestinal hyperactivity.

• C. Tetanus: Usually follows an infected wound and causes stimulus-induced spasms rather than this medication-associated syndrome.
• B. Heat exhaustion: Does not adequately explain severe lead-pipe rigidity and marked CK elevation.
• E. Acute dystonia: Produces focal or regional abnormal muscle contractions without severe systemic hyperthermia and rhabdomyolysis.

Clinical safety point Do not mistake the severe rigidity for an uncomplicated extrapyramidal adverse effect

The causative medication must be stopped immediately. The patient requires intensive monitoring, cooling, intravenous fluid therapy, prevention and treatment of kidney injury, and management of respiratory, cardiovascular, and electrolyte complications.

Why the other options are less appropriate

• A. Administer another dose of haloperidol: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Give an SSRI: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Begin outpatient physical therapy: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Discharge when the temperature falls below 39°C: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not mistake the severe rigidity for an uncomplicated extrapyramidal adverse effect

A urine dipstick that is positive for heme despite few or no red blood cells suggests myoglobin. Severe muscle rigidity and breakdown release myoglobin, which can contribute to acute kidney injury.

Why the other options are less appropriate

• A. Glomerulonephritis: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Nephrotic syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Uncomplicated cystitis: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Renal calculi: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not mistake the severe rigidity for an uncomplicated extrapyramidal adverse effect

Severe cases may be treated with dantrolene to reduce muscle contraction or a dopamine agonist such as bromocriptine. Evidence is less definitive than for immediate withdrawal and supportive treatment, which remain essential.

Why the other options are less appropriate

• B. Sumatriptan: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Physostigmine: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Flumazenil: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Protamine sulfate: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not mistake the severe rigidity for an uncomplicated extrapyramidal adverse effect

Gastrointestinal symptoms, confusion, characteristic visual disturbance, bradyarrhythmia, ventricular ectopy, renal impairment, hyperkalemia, and elevated digoxin concentration indicate clinically significant digoxin toxicity.

Why the other options are less appropriate

• A. Stable atrial fibrillation: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Acute bacterial gastroenteritis: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Hyperthyroidism: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Isolated furosemide adverse effects: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not determine severity from the serum digoxin concentration alone

Digoxin is substantially cleared through the kidneys and has a narrow therapeutic index. Amiodarone can increase digoxin exposure through pharmacokinetic interaction. Renal deterioration further increases the risk of accumulation.

Why the other options are less appropriate

• A. Improved kidney function: does not explain the complete pattern of history, examination findings, and available investigations.
• B. A high-fibre breakfast: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Stopping acetaminophen: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Increased physical activity: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not determine severity from the serum digoxin concentration alone

Digoxin immune Fab is indicated for potentially life-threatening toxicity, including serious ventricular arrhythmia, severe bradyarrhythmia or heart block, hemodynamic instability, and clinically significant hyperkalemia associated with toxicity.

Why the other options are less appropriate

• A. Naloxone: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Vitamin K: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. N-acetylcysteine: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Protamine: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not determine severity from the serum digoxin concentration alone

Digoxin toxicity is a clinical diagnosis supported by laboratory data. Levels can be misleading if measured too soon after a dose, and total digoxin measurements become difficult to interpret after immune Fab because assays may detect bound digoxin.

Why the other options are less appropriate

• B. The serum level always correlates precisely with clinical severity: is less consistent with the full clinical context and is not the single best answer.
• C. A normal level always excludes toxicity: is less consistent with the full clinical context and is not the single best answer.
• D. Levels remain directly interpretable immediately after digoxin immune Fab: is less consistent with the full clinical context and is not the single best answer.
• E. Serum measurement is unnecessary in every circumstance: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not determine severity from the serum digoxin concentration alone

Coarse tremor, ataxia, dysarthria, confusion, gastrointestinal symptoms, renal impairment, and elevated lithium in a patient taking several medications that reduce lithium clearance indicate chronic lithium toxicity.

Why the other options are less appropriate

• A. Acute cerebellar stroke only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Serotonin syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Hyperthyroidism: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Uncomplicated viral gastroenteritis: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not use activated charcoal as the primary gastrointestinal decontamination treatment because lithium is not effectively adsorbed

Volume depletion increases proximal sodium and lithium reabsorption. Thiazides, NSAIDs, and ACE inhibitors can reduce renal lithium clearance and precipitate toxicity.

Why the other options are less appropriate

• A. Psyllium and probiotics: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Increased dietary fibre and vitamin C: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Acetaminophen and calcium carbonate: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Salbutamol and an inhaled corticosteroid: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not use activated charcoal as the primary gastrointestinal decontamination treatment because lithium is not effectively adsorbed

Lithium and contributing medications should be stopped. The patient requires emergency assessment, isotonic fluid resuscitation when appropriate, serial lithium measurements, electrolyte and renal monitoring, and evaluation for hemodialysis.

Activated charcoal does not effectively bind lithium.

Why the other options are less appropriate

• A. Continue lithium and repeat the level next month: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Restrict sodium and fluids: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Treat with activated charcoal alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Give a potassium-based salt substitute: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not use activated charcoal as the primary gastrointestinal decontamination treatment because lithium is not effectively adsorbed

Extracorporeal treatment is recommended for severe lithium poisoning, particularly with markedly reduced consciousness, seizures, or dangerous dysrhythmias. Renal impairment and lithium concentration also influence the decision.

Why the other options are less appropriate

• B. Mild nausea only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Fine tremor without confusion: is less consistent with the full clinical context and is not the single best answer.
• D. Stable kidney function: is less consistent with the full clinical context and is not the single best answer.
• E. Normal mental status: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not use activated charcoal as the primary gastrointestinal decontamination treatment because lithium is not effectively adsorbed

Profound high-anion-gap metabolic acidosis, markedly elevated lactate, shock, acute renal failure, and continued metformin exposure strongly suggest metformin-associated lactic acidosis.

Why the other options are less appropriate

• A. Mild medication intolerance: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Hyperosmolar hyperglycemic state: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Respiratory alkalosis only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Diabetic ketoacidosis caused by severe hyperglycemia: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not attribute severe lactate elevation automatically to metformin without also investigating sepsis, shock, ischemia, and other causes

Diarrhea, poor intake, ACE-inhibitor use, and NSAID exposure can combine to produce acute kidney injury. Reduced renal clearance permits metformin accumulation, while shock further increases lactate production.

Why the other options are less appropriate

• A. High calcium intake: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Excess insulin administration: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Hyperventilation causing lactate accumulation: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Vitamin B12 supplementation: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not attribute severe lactate elevation automatically to metformin without also investigating sepsis, shock, ischemia, and other causes

This is a life-threatening metabolic emergency. Management includes airway and circulatory support, stopping metformin, treating shock and any precipitating illness, correcting glucose and electrolytes, and considering extracorporeal treatment.

Why the other options are less appropriate

• A. Continue metformin because the glucose is normal: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Begin an outpatient ketogenic diet: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Give an oral bicarbonate supplement and discharge: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Restrict intravenous fluids completely: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not attribute severe lactate elevation automatically to metformin without also investigating sepsis, shock, ischemia, and other causes

EXTRIP recommends extracorporeal treatment in severe metformin poisoning, especially with extreme lactic acidosis, pH at or below approximately 7.0, failure of supportive treatment, shock, altered consciousness, or major renal impairment.

Why the other options are less appropriate

• A. Lactate of 2.5 mmol/L with normal pH: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Stable chronic metformin use without symptoms: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Mild nausea with normal renal function: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. HbA1c of 7.2%: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not attribute severe lactate elevation automatically to metformin without also investigating sepsis, shock, ischemia, and other causes

The patient has ketonemia, high-anion-gap metabolic acidosis, and DKA symptoms despite a glucose level below the range usually associated with conventional DKA. SGLT2-inhibitor use, fasting, surgery, and insulin omission are major clues.

Why the other options are less appropriate

• A. Hyperosmolar hyperglycemic state: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Respiratory alkalosis caused by anxiety: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Acute appendicitis only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Starvation without metabolic acidosis: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not withhold insulin because the patient is euglycemic; insulin is necessary to stop ketone production

SGLT2 inhibitors increase urinary glucose loss, so substantial ketoacidosis may develop without marked hyperglycemia. Diagnosis depends on acid-base status and ketone production, not glucose alone.

Why the other options are less appropriate

• B. Measuring beta-hydroxybutyrate: is less consistent with the full clinical context and is not the single best answer.
• C. Calculating the anion gap: is less consistent with the full clinical context and is not the single best answer.
• D. Asking about medication use: is less consistent with the full clinical context and is not the single best answer.
• E. Checking blood pH: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not withhold insulin because the patient is euglycemic; insulin is necessary to stop ketone production

Insulin is required to suppress lipolysis and ketogenesis. Because glucose is only mildly elevated, dextrose is usually required earlier than in conventional DKA so insulin can continue safely until ketones clear and the anion gap closes.

Why the other options are less appropriate

• A. Restrict fluids and carbohydrates: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Give dextrose alone without insulin: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Continue dapagliflozin to clear ketones: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Discharge because the glucose is not severely elevated: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not withhold insulin because the patient is euglycemic; insulin is necessary to stop ketone production

Patients should receive clear sick-day and perioperative instructions. SGLT2 inhibitors generally need to be withheld before planned surgery according to agent-specific guidance, while insulin should not be stopped without a medically supervised plan.

Why the other options are less appropriate

• A. Stop basal insulin whenever fasting: is less consistent with the full clinical context and is not the single best answer.
• B. Continue the SGLT2 inhibitor during every acute illness: is less consistent with the full clinical context and is not the single best answer.
• D. Check only urine glucose during illness: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Use a ketogenic diet immediately before surgery: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not withhold insulin because the patient is euglycemic; insulin is necessary to stop ketone production

Sudden focal deficits, headache, vomiting, reduced consciousness, severe hypertension, anticoagulant exposure, and blood visible on noncontrast CT confirm intracerebral hemorrhage.

Why the other options are less appropriate

• A. Acute ischemic stroke: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Hypoglycemia without stroke: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Bell palsy: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Migraine with aura: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not give aspirin to a patient with focal neurologic deficits until intracranial hemorrhage has been excluded

Anticoagulant-associated intracranial hemorrhage is a medical emergency. Priorities include airway protection, neurosurgical and stroke evaluation, rapid anticoagulant reversal, controlled blood-pressure treatment, and management of intracranial complications.

Why the other options are less appropriate

• A. Administer another dose of apixaban: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Perform lumbar puncture: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Discharge if the headache improves: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Give aspirin immediately: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not give aspirin to a patient with focal neurologic deficits until intracranial hemorrhage has been excluded

Andexanet alfa is a targeted reversal agent for factor Xa inhibitors. When it is unavailable or unsuitable, a four-factor prothrombin complex concentrate may be used according to institutional protocols.

• Idarucizumab reverses dabigatran.
• Vitamin K reverses warfarin over time.
• Protamine is primarily used for unfractionated heparin and partially for low-molecular-weight heparin.

Why the other options are less appropriate

• A. N-acetylcysteine: is less consistent with the full clinical context and is not the single best answer.
• B. Idarucizumab: is less consistent with the full clinical context and is not the single best answer.
• C. Vitamin K alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Protamine sulfate: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not give aspirin to a patient with focal neurologic deficits until intracranial hemorrhage has been excluded

Intracerebral hemorrhage has already been demonstrated by CT. Lumbar puncture provides no benefit in this setting and may create additional bleeding or intracranial-pressure risk.

Why the other options are less appropriate

• A. Repeat noncontrast CT when clinically indicated: is less consistent with the full clinical context and is not the single best answer.
• B. CT angiography when indicated: is less consistent with the full clinical context and is not the single best answer.
• D. CBC and coagulation assessment: is less consistent with the full clinical context and is not the single best answer.
• E. Medication reconciliation: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not give aspirin to a patient with focal neurologic deficits until intracranial hemorrhage has been excluded

Profound reduction in consciousness, severe hypoventilation, hypoxemia, and pinpoint pupils strongly indicate opioid poisoning. The immediate danger is respiratory arrest.

Why the other options are less appropriate

• A. Acute psychosis: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Serotonin syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Anticholinergic poisoning: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Simple alcohol intoxication without respiratory compromise: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not focus on obtaining a drug history while the patient is apneic or severely hypoventilating

Airway and breathing support must begin immediately. Naloxone should be administered promptly, but it does not replace ventilation, oxygenation, emergency activation, or ongoing monitoring.

Why the other options are less appropriate

• B. Wait for toxicology results: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Give activated charcoal before supporting breathing: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Place the patient alone in a recovery room: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Give flumazenil: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not focus on obtaining a drug history while the patient is apneic or severely hypoventilating

Naloxone’s clinical effect may be shorter than that of the opioid. Recurrent toxicity can occur, particularly with potent, long-acting, or sustained-release opioids. Repeat dosing or an infusion may be required under emergency supervision.

Why the other options are less appropriate

• A. Opioids cannot cause recurrent respiratory depression: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Naloxone permanently worsens opioid toxicity: does not explain the complete pattern of history, examination findings, and available investigations.
• C. The initial diagnosis was impossible: does not explain the complete pattern of history, examination findings, and available investigations.
• E. The patient is experiencing isolated anxiety: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not focus on obtaining a drug history while the patient is apneic or severely hypoventilating

Naloxone should be titrated to restore effective breathing. Excessive dosing can precipitate acute withdrawal, agitation, vomiting, aspiration risk, and sympathetic activation in an opioid-dependent patient.

Why the other options are less appropriate

• A. Force the patient into severe withdrawal: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Produce complete alertness in every patient: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Normalize pupil size only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Eliminate the need for observation: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not focus on obtaining a drug history while the patient is apneic or severely hypoventilating

For a single acute ingestion with a known time, a concentration obtained at least four hours after ingestion is interpreted using the acetaminophen treatment nomogram. A level obtained earlier may not reflect completed absorption.

Why the other options are less appropriate

• A. Wait for jaundice to develop: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Reassure her because liver enzymes are normal: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Order a serum lithium level only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Perform colonoscopy: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not apply the standard nomogram to repeated supratherapeutic ingestion or an unknown ingestion time

Patients may initially be asymptomatic with normal AST and ALT despite a potentially hepatotoxic exposure. Waiting for biochemical injury before evaluating or treating can result in preventable hepatic failure.

Why the other options are less appropriate

• B. Acetaminophen never affects liver enzymes: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• C. Liver injury occurs only within the first hour: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Normal AST always excludes toxicity: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• E. Jaundice must occur before treatment: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.

Clinical safety point Do not apply the standard nomogram to repeated supratherapeutic ingestion or an unknown ingestion time

N-acetylcysteine replenishes glutathione and helps detoxify the reactive acetaminophen metabolite. It is most effective when given early but can still benefit patients who present late or have established hepatic injury.

Why the other options are less appropriate

• A. Idarucizumab: is less consistent with the full clinical context and is not the single best answer.
• B. Naloxone: is less consistent with the full clinical context and is not the single best answer.
• C. Digoxin immune Fab: is less consistent with the full clinical context and is not the single best answer.
• D. Fomepizole alone for every ingestion: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not apply the standard nomogram to repeated supratherapeutic ingestion or an unknown ingestion time

N-acetylcysteine should not be delayed when a potentially toxic ingestion occurred and obtaining or interpreting the concentration would push treatment beyond the period when early therapy is most protective.

Why the other options are less appropriate

• A. A negative pregnancy test: is less consistent with the full clinical context and is not the single best answer.
• B. One normal therapeutic dose: is less consistent with the full clinical context and is not the single best answer.
• D. Normal vital signs: is less consistent with the full clinical context and is not the single best answer.
• E. Mild nausea after eating: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not apply the standard nomogram to repeated supratherapeutic ingestion or an unknown ingestion time

Glyburide stimulates pancreatic insulin release. Excess exposure, poor food intake, older age, and kidney dysfunction can produce severe and prolonged hypoglycemia that recurs after initial dextrose treatment.

Why the other options are less appropriate

• A. Acute hyperthyroidism: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Diabetic ketoacidosis: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Hyperosmolar hyperglycemic state: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Serotonin syndrome: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not discharge a patient with sulfonylurea-associated hypoglycemia after a single response to dextrose

Dextrose corrects the immediate glucose deficit but may stimulate further endogenous insulin secretion. Because the sulfonylurea remains active, another fall in glucose can follow.

Why the other options are less appropriate

• A. Dextrose blocks insulin receptors permanently: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• C. Dextrose causes immediate kidney failure: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• D. Sulfonylureas prevent glucose absorption from the intestine: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• E. Dextrose neutralizes octreotide: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.

Clinical safety point Do not discharge a patient with sulfonylurea-associated hypoglycemia after a single response to dextrose

Octreotide suppresses pancreatic insulin release and is commonly used with dextrose in clinically significant sulfonylurea poisoning. Glucose must still be corrected immediately, and frequent monitoring remains necessary.

Why the other options are less appropriate

• A. Regular insulin: is less consistent with the full clinical context and is not the single best answer.
• B. Glucagon as continuous definitive monotherapy: is less consistent with the full clinical context and is not the single best answer.
• C. Metformin: is less consistent with the full clinical context and is not the single best answer.
• E. Dapagliflozin: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not discharge a patient with sulfonylurea-associated hypoglycemia after a single response to dextrose

Sulfonylurea hypoglycemia may recur after apparent recovery, especially with long-acting agents, older age, kidney dysfunction, or overdose. The patient requires prolonged monitored observation after treatment ends.

Why the other options are less appropriate

• B. Discharge immediately after one normal glucose reading: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Resume glyburide at a higher dose: is less consistent with the full clinical context and is not the single best answer.
• D. Send the patient home alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Restrict all carbohydrates for 24 hours: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not discharge a patient with sulfonylurea-associated hypoglycemia after a single response to dextrose

Verapamil overdose can cause severe bradycardia, atrioventricular block, reduced myocardial contractility, vasodilation, hypotension, hyperglycemia, lactic acidosis, and shock.

Why the Other Options Are Incorrect

• B: Opioid poisoning primarily causes respiratory depression and reduced consciousness.
• C: Serotonin syndrome produces clonus, hyperreflexia, and hyperthermia.
• D: Adrenal crisis may cause hypotension but usually includes hyponatremia, hyperkalemia, and hypoglycemia.
• E: Organophosphate poisoning causes marked secretions, miosis, bronchospasm, and muscle fasciculations.

Clinical safety point Atropine may be attempted, but severe poisoning commonly requires high-dose insulin and vasopressor therapy rather than atropine alone

Calcium-channel blockade impairs insulin release from pancreatic beta cells and reduces myocardial glucose utilization. Hyperglycemia is therefore a useful clue in severe calcium-channel blocker poisoning.

Why the other options are less appropriate

• B. Severe hypoglycemia in every patient: is less consistent with the full clinical context and is not the single best answer.
• C. Hyperreflexia: is less consistent with the full clinical context and is not the single best answer.
• D. Urinary retention and dry skin: is less consistent with the full clinical context and is not the single best answer.
• E. Markedly elevated acetaminophen concentration: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Atropine may be attempted, but severe poisoning commonly requires high-dose insulin and vasopressor therapy rather than atropine alone

High-dose insulin supports myocardial carbohydrate utilization and improves cardiac contractility. Glucose and potassium must be monitored frequently because treatment can cause hypoglycemia and intracellular potassium shifting.

Vasopressors, intravenous calcium, appropriate fluids, and other critical-care interventions may also be required.

Why the other options are less appropriate

• A. Fluid restriction: is less consistent with the full clinical context and is not the single best answer.
• B. Additional verapamil: is less consistent with the full clinical context and is not the single best answer.
• C. Digoxin: is less consistent with the full clinical context and is not the single best answer.
• D. Oral hydrochlorothiazide: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Atropine may be attempted, but severe poisoning commonly requires high-dose insulin and vasopressor therapy rather than atropine alone

Amlodipine, diltiazem, and verapamil are not effectively removed by conventional extracorporeal treatment. Dialysis may still be needed for a separate indication, such as severe renal failure, but not specifically to remove these medications.

Why the other options are less appropriate

• A. It is the definitive treatment for every verapamil overdose: is less consistent with the full clinical context and is not the single best answer.
• B. It should replace high-dose insulin: is less consistent with the full clinical context and is not the single best answer.
• D. It is required whenever glucose is elevated: is less consistent with the full clinical context and is not the single best answer.
• E. It reliably corrects shock within minutes: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Atropine may be attempted, but severe poisoning commonly requires high-dose insulin and vasopressor therapy rather than atropine alone

Propranolol overdose can produce severe bradycardia, hypotension, hypoglycemia, seizures, and wide-complex cardiac toxicity.

Propranolol is highly lipophilic and also blocks cardiac sodium channels in large overdoses.

Why the other options are less appropriate

• A. Acute opioid withdrawal: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Anticholinergic toxicity: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Thyroid storm: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Salicylate poisoning: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Cardiac pacing may not correct the underlying loss of myocardial contractility

The patient has life-threatening neurologic and cardiovascular toxicity. Airway protection, ventilation, circulation, glucose, seizures, and cardiac conduction must be addressed immediately.

Why the other options are less appropriate

• A. Induced vomiting: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Exercise to increase the heart rate: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Oral rehydration only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Outpatient ECG monitoring: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Cardiac pacing may not correct the underlying loss of myocardial contractility

High-dose insulin can improve myocardial contractility and is recommended for severe beta-blocker–induced cardiogenic shock. Treatment requires close glucose, potassium, fluid-balance, and hemodynamic monitoring.

Why the other options are less appropriate

• A. Long-acting propranolol: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Furosemide: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Warfarin: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Intravenous acetaminophen: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Cardiac pacing may not correct the underlying loss of myocardial contractility

Propranolol can block fast cardiac sodium channels. Sodium bicarbonate may be used when severe QRS widening or sodium-channel–mediated cardiotoxicity is present.

Why the other options are less appropriate

• A. Calcium carbonate by mouth: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Vitamin K: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Naloxone: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Pralidoxime: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Cardiac pacing may not correct the underlying loss of myocardial contractility

Methanol is metabolized to formic acid, which causes severe high-anion-gap metabolic acidosis and characteristic optic-nerve and retinal toxicity.

Why the other options are less appropriate

• B. Ethanol intoxication only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Opioid poisoning: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Acute angle-closure glaucoma only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Carbon monoxide poisoning: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not wait for blindness or a confirmed methanol concentration before starting an alcohol-dehydrogenase inhibitor when suspicion is high

Fomepizole inhibits alcohol dehydrogenase, preventing methanol from being metabolized into formaldehyde and formic acid.

Treatment should begin promptly when clinically significant methanol poisoning is suspected rather than waiting for every confirmatory result.

Why the other options are less appropriate

• A. Digoxin immune Fab: is less consistent with the full clinical context and is not the single best answer.
• B. Naloxone: is less consistent with the full clinical context and is not the single best answer.
• C. Flumazenil: is less consistent with the full clinical context and is not the single best answer.
• D. Atropine: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not wait for blindness or a confirmed methanol concentration before starting an alcohol-dehydrogenase inhibitor when suspicion is high

Visual toxicity indicates clinically severe methanol poisoning. Other dialysis indications include coma, seizure, severe acidemia, persistent acidosis, and sufficiently high methanol concentrations.

Why the other options are less appropriate

• A. Mild nausea only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Normal mental status with no acidosis: is less consistent with the full clinical context and is not the single best answer.
• D. One therapeutic ethanol drink: is less consistent with the full clinical context and is not the single best answer.
• E. Normal renal function: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not wait for blindness or a confirmed methanol concentration before starting an alcohol-dehydrogenase inhibitor when suspicion is high

Early poisoning may produce a high osmolal gap before severe acidosis develops. Later, the osmolal gap may normalize as methanol is metabolized while the anion gap and clinical toxicity worsen.

Why the other options are less appropriate

• B. A normal osmolal gap always excludes methanol poisoning: is less consistent with the full clinical context and is not the single best answer.
• C. The osmolal gap becomes elevated only after all methanol is metabolized: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. It directly measures formic acid concentration: is less consistent with the full clinical context and is not the single best answer.
• E. It replaces clinical assessment and blood-gas testing: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not wait for blindness or a confirmed methanol concentration before starting an alcohol-dehydrogenase inhibitor when suspicion is high

Ethylene glycol produces high-anion-gap metabolic acidosis, kidney injury, hypocalcemia, and urinary calcium-oxalate crystals.

Why the other options are less appropriate

• A. Acute salicylate poisoning: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Methanol poisoning: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Diabetic ketoacidosis: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Uncomplicated ethanol intoxication: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point A declining osmolal gap may reflect metabolism into more dangerous acids rather than recovery

Alcohol dehydrogenase converts ethylene glycol into several toxic metabolites. Glycolic acid is a major contributor to the high-anion-gap metabolic acidosis.

Oxalic acid binds calcium and contributes to calcium-oxalate deposition and renal injury.

Why the other options are less appropriate

• A. Salicylic acid: is less consistent with the full clinical context and is not the single best answer.
• B. Formic acid: is less consistent with the full clinical context and is not the single best answer.
• C. Acetaldehyde: is less consistent with the full clinical context and is not the single best answer.
• D. Cyanocobalamin: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point A declining osmolal gap may reflect metabolism into more dangerous acids rather than recovery

Fomepizole prevents formation of toxic metabolites by inhibiting alcohol dehydrogenase.

Treatment should begin promptly when significant exposure is suspected.

Why the other options are less appropriate

• A. Physostigmine: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Hydroxocobalamin: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Naloxone: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Vitamin K: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point A declining osmolal gap may reflect metabolism into more dangerous acids rather than recovery

EXTRIP recommends extracorporeal treatment in severe ethylene-glycol poisoning based on glycolate concentration, anion gap, clinical deterioration, or severe kidney injury.

Why the other options are less appropriate

• B. Normal acid-base status: is less consistent with the full clinical context and is not the single best answer.
• C. Mild isolated nausea: is less consistent with the full clinical context and is not the single best answer.
• D. Normal kidney function and no symptoms: is less consistent with the full clinical context and is not the single best answer.
• E. One calcium-oxalate crystal without a compatible history: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point A declining osmolal gap may reflect metabolism into more dangerous acids rather than recovery

Salicylates directly stimulate the respiratory centre, causing respiratory alkalosis. Organic-acid accumulation subsequently produces high-anion-gap metabolic acidosis.

A near-normal or alkalemic pH does not mean the poisoning is mild.

Why the other options are less appropriate

• A. Isolated respiratory acidosis: is less consistent with the full clinical context and is not the single best answer.
• C. Isolated non-anion-gap metabolic acidosis: is less consistent with the full clinical context and is not the single best answer.
• D. Metabolic alkalosis only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Normal acid-base status: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not interpret an alkalemic pH as evidence that severe salicylate toxicity is absent

Serum and urine alkalinization reduces salicylate penetration into tissues and increases renal elimination. Hypokalemia must be corrected because potassium depletion interferes with effective urine alkalinization.

Why the other options are less appropriate

• A. Fluid restriction: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Urine acidification: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Naloxone: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Oral calcium supplementation: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not interpret an alkalemic pH as evidence that severe salicylate toxicity is absent

The patient’s extreme hyperventilation is compensatory. Sedation, paralysis, or insufficient ventilator settings may cause carbon-dioxide retention and falling pH, increasing the nonionized salicylate fraction and CNS penetration.

Why the other options are less appropriate

• A. Mechanical ventilation neutralizes bicarbonate: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• B. Salicylates cause complete resistance to oxygen: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• C. Intubation always increases kidney clearance: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• E. Aspirin immediately obstructs the endotracheal tube: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.

Clinical safety point Do not interpret an alkalemic pH as evidence that severe salicylate toxicity is absent

Neurologic deterioration, hypoxemia or pulmonary edema, severe acidosis, renal failure, or a very high salicylate concentration can indicate the need for emergency dialysis.

Why the other options are less appropriate

• A. Normal respiratory rate: is less consistent with the full clinical context and is not the single best answer.
• B. Mild tinnitus with improving symptoms: is less consistent with the full clinical context and is not the single best answer.
• C. Normal renal function and stable acid-base status: is less consistent with the full clinical context and is not the single best answer.
• D. One therapeutic aspirin dose: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not interpret an alkalemic pH as evidence that severe salicylate toxicity is absent

Amitriptyline toxicity causes anticholinergic manifestations, seizures, hypotension, and cardiac sodium-channel blockade resulting in QRS widening.

Why the other options are less appropriate

• A. Opioid poisoning: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Organophosphate toxicity: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Beta-blocker toxicity: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Acute lithium toxicity: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not administer a class IA or IC antiarrhythmic to treat tricyclic-induced wide-complex dysrhythmia

Sodium bicarbonate increases serum sodium and alkalinizes the blood, reducing tricyclic binding to cardiac sodium channels and improving conduction and blood pressure.

Why the other options are less appropriate

• B. Intravenous calcium gluconate only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Digoxin: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Physostigmine: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Flumazenil: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not administer a class IA or IC antiarrhythmic to treat tricyclic-induced wide-complex dysrhythmia

Benzodiazepines are generally preferred for toxin-induced seizures. Seizure control also reduces acidosis, which can worsen tricyclic cardiotoxicity.

Why the other options are less appropriate

• A. Haloperidol as first-line therapy: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Physostigmine: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Flumazenil: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Additional amitriptyline: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not administer a class IA or IC antiarrhythmic to treat tricyclic-induced wide-complex dysrhythmia

Although physostigmine can reverse some anticholinergic findings, it can aggravate conduction abnormalities and provoke bradyarrhythmia or seizure in tricyclic antidepressant poisoning.

Why the other options are less appropriate

• A. Norepinephrine: is less consistent with the full clinical context and is not the single best answer.
• B. Sodium bicarbonate: is less consistent with the full clinical context and is not the single best answer.
• D. Benzodiazepine: is less consistent with the full clinical context and is not the single best answer.
• E. Intravenous fluid: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not administer a class IA or IC antiarrhythmic to treat tricyclic-induced wide-complex dysrhythmia

The patient has a cholinergic toxidrome involving muscarinic, nicotinic, and central nervous system effects.

Why the other options are less appropriate

• A. Serotonin syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Anticholinergic poisoning: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Opioid withdrawal: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Diabetic ketoacidosis: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not stop atropine merely because the heart rate becomes elevated if dangerous respiratory secretions remain

Atropine antagonizes muscarinic acetylcholine receptors. Doses are repeated and escalated until bronchial secretions and bronchospasm are controlled and oxygenation improves.

Pupil size is not the principal target of atropine therapy.

Why the other options are less appropriate

• B. Naloxone: is less consistent with the full clinical context and is not the single best answer.
• C. Flumazenil: is less consistent with the full clinical context and is not the single best answer.
• D. Physostigmine: is less consistent with the full clinical context and is not the single best answer.
• E. Cyproheptadine: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not stop atropine merely because the heart rate becomes elevated if dangerous respiratory secretions remain

Pralidoxime can reactivate acetylcholinesterase before the organophosphate-enzyme complex undergoes irreversible aging. It is especially relevant to muscle weakness and respiratory failure.

Why the other options are less appropriate

• A. Fomepizole: is less consistent with the full clinical context and is not the single best answer.
• B. Vitamin K: is less consistent with the full clinical context and is not the single best answer.
• D. Hydroxocobalamin: is less consistent with the full clinical context and is not the single best answer.
• E. Digoxin immune Fab: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not stop atropine merely because the heart rate becomes elevated if dangerous respiratory secretions remain

Residual pesticide can expose clinicians and rescuers. Contaminated clothing should be removed and contained, and the skin irrigated according to hazardous-material protocols.

Why the other options are less appropriate

• A. Begin mouth-to-mouth ventilation without a barrier: is less consistent with the full clinical context and is not the single best answer.
• C. Keep contaminated clothing beside the patient: is less consistent with the full clinical context and is not the single best answer.
• D. Induce vomiting: is less consistent with the full clinical context and is not the single best answer.
• E. Perform deep-tissue massage: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not stop atropine merely because the heart rate becomes elevated if dangerous respiratory secretions remain

Enclosed-space smoke exposure, severe unexplained lactic acidosis, altered consciousness, and cardiovascular collapse suggest cyanide toxicity.

Burning plastics and synthetic materials may release hydrogen cyanide.

Why the other options are less appropriate

• A. Methemoglobinemia caused by nitrate-contaminated water: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Isolated ethanol intoxication: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Iron deficiency: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Digoxin toxicity: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not wait for a blood cyanide concentration, which is generally unavailable rapidly enough to guide emergency treatment

Cyanide inhibits cellular oxidative phosphorylation. Oxygen may be delivered in arterial blood but cannot be used normally by mitochondria.

Why the other options are less appropriate

• A. Cyanide affects only the kidneys: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Cyanide increases tissue oxygen use: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• C. Pulse oximetry directly measures mitochondrial function: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• E. The lactate result must therefore be incorrect: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.

Clinical safety point Do not wait for a blood cyanide concentration, which is generally unavailable rapidly enough to guide emergency treatment

Hydroxocobalamin binds cyanide and forms cyanocobalamin, which can be eliminated in the urine. It can be administered empirically when severe cyanide poisoning is strongly suspected.

Why the other options are less appropriate

• A. Naloxone: is less consistent with the full clinical context and is not the single best answer.
• C. Atropine: is less consistent with the full clinical context and is not the single best answer.
• D. Fomepizole: is less consistent with the full clinical context and is not the single best answer.
• E. N-acetylcysteine: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not wait for a blood cyanide concentration, which is generally unavailable rapidly enough to guide emergency treatment

Cyanide and carbon monoxide exposures can coexist in smoke-inhalation victims. Carbon monoxide should be assessed with co-oximetry, and high-concentration oxygen should be administered.

Why the other options are less appropriate

• B. Lithium poisoning: is less consistent with the full clinical context and is not the single best answer.
• C. Salicylate poisoning: is less consistent with the full clinical context and is not the single best answer.
• D. Digoxin poisoning: is less consistent with the full clinical context and is not the single best answer.
• E. Methotrexate toxicity: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not wait for a blood cyanide concentration, which is generally unavailable rapidly enough to guide emergency treatment

Rapidly increasing carbon-dioxide production, muscle rigidity, tachycardia, hyperkalemia, acidosis, rhabdomyolysis, and hyperthermia following triggering anesthesia indicate malignant hyperthermia.

Why the other options are less appropriate

• A. Serotonin syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Neuroleptic malignant syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Thyroid storm: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Septic shock: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Dantrolene does not treat ordinary exertional or environmental heat stroke

Dantrolene reduces uncontrolled calcium release within skeletal muscle and is the accepted specific treatment for malignant hyperthermia.

Why the other options are less appropriate

• A. Naloxone: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Cyproheptadine: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Bromocriptine: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Fomepizole: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Dantrolene does not treat ordinary exertional or environmental heat stroke

A rapidly increasing end-tidal CO₂ despite adequate ventilation is often an early sign of uncontrolled skeletal-muscle metabolism. Hyperthermia may develop later.

Why the other options are less appropriate

• A. Purpuric rash: is less consistent with the full clinical context and is not the single best answer.
• B. Jaundice: is less consistent with the full clinical context and is not the single best answer.
• C. Pinpoint pupils: is less consistent with the full clinical context and is not the single best answer.
• D. Severe hypoglycemia: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Dantrolene does not treat ordinary exertional or environmental heat stroke

All triggering agents must be stopped. Emergency management includes hyperventilation with high-flow oxygen, dantrolene, active cooling when appropriate, treatment of hyperkalemia and acidosis, and intensive monitoring.

Why the other options are less appropriate

• A. Replace dantrolene with a calcium-channel blocker: is less consistent with the full clinical context and is not the single best answer.
• B. Increase their dose: is less consistent with the full clinical context and is not the single best answer.
• C. Continue until the temperature normalizes: is less consistent with the full clinical context and is not the single best answer.
• E. Stop oxygen administration: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Dantrolene does not treat ordinary exertional or environmental heat stroke

Early neurologic symptoms followed by seizure and cardiovascular collapse after local-anesthetic administration are characteristic of local-anesthetic systemic toxicity, or LAST.

Why the other options are less appropriate

• A. Vasovagal syncope only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Acute bacterial meningitis: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Serotonin syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Opioid withdrawal: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not use additional lidocaine as the first antiarrhythmic treatment for local-anesthetic toxicity

Stopping further exposure is essential. The airway should be supported and hypoxemia, hypercapnia, and acidosis prevented because these can worsen local-anesthetic cardiotoxicity.

Why the other options are less appropriate

• A. Complete the planned dose: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Remove oxygen: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Ask the patient to walk: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Give an oral antihistamine: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not use additional lidocaine as the first antiarrhythmic treatment for local-anesthetic toxicity

Intravenous lipid emulsion is a central component of treatment for severe LAST with seizure, cardiovascular instability, or cardiac arrest.

Why the other options are less appropriate

• B. Vitamin K: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Protamine sulfate: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Digoxin immune Fab: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Fomepizole: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not use additional lidocaine as the first antiarrhythmic treatment for local-anesthetic toxicity

Benzodiazepines are preferred for local-anesthetic–induced seizure. Large propofol doses may worsen cardiovascular instability.

Why the other options are less appropriate

• A. Class IC antiarrhythmics: is less consistent with the full clinical context and is not the single best answer.
• B. Tricyclic antidepressants: is less consistent with the full clinical context and is not the single best answer.
• C. Large-dose propofol in a severely unstable patient: is less consistent with the full clinical context and is not the single best answer.
• D. Additional bupivacaine: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not use additional lidocaine as the first antiarrhythmic treatment for local-anesthetic toxicity

A platelet reduction greater than 50%, onset approximately five to ten days after heparin exposure, and new thrombosis strongly suggest immune-mediated HIT.

Why the other options are less appropriate

• B. Immune thrombocytopenia: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Thrombotic thrombocytopenic purpura: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Aplastic anemia: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Vitamin K deficiency: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point HIT is primarily a thrombotic disorder, not a bleeding disorder

The 4Ts score evaluates:

• Degree of thrombocytopenia
• Timing of platelet reduction
• Thrombosis or related complications
• Other possible explanations for thrombocytopenia

Why the other options are less appropriate

• A. APGAR score: is less consistent with the full clinical context and is not the single best answer.
• B. Wells score for pulmonary embolism only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Glasgow Coma Scale: is less consistent with the full clinical context and is not the single best answer.
• D. CURB-65: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point HIT is primarily a thrombotic disorder, not a bleeding disorder

All heparin sources—including infusions, injections, flushes, and heparin-coated devices when relevant—should be stopped. Because HIT is highly prothrombotic, alternative anticoagulation is usually required unless contraindicated.

Why the other options are less appropriate

• A. Continue heparin until the antibody result returns: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Give a platelet transfusion routinely: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Start warfarin alone immediately: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Stop anticoagulation because the platelet count is low: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point HIT is primarily a thrombotic disorder, not a bleeding disorder

Warfarin can produce a transient hypercoagulable state during acute HIT. It should generally be delayed until platelet recovery and overlapped appropriately with a non-heparin anticoagulant.

Why the other options are less appropriate

• A. It prevents laboratory confirmation: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• B. It immediately raises the platelet count: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• C. It reverses HIT antibodies: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• E. It has no anticoagulant activity: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.

Clinical safety point HIT is primarily a thrombotic disorder, not a bleeding disorder

Hemodynamic instability, major hemoglobin reduction, supratherapeutic INR, and retroperitoneal bleeding constitute life-threatening anticoagulant-associated hemorrhage.

Why the other options are less appropriate

• A. Renal colic without bleeding: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Uncomplicated muscle strain: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Acute pyelonephritis only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Stable chronic anemia: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Vitamin K alone does not reverse life-threatening warfarin bleeding rapidly enough

Four-factor PCC rapidly replaces vitamin K–dependent coagulation factors. Intravenous vitamin K is also needed because PCC has a limited duration while warfarin’s effect persists.

Why the other options are less appropriate

• B. Oral vitamin K alone: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Aspirin: is less consistent with the full clinical context and is not the single best answer.
• D. Protamine sulfate: is less consistent with the full clinical context and is not the single best answer.
• E. Idarucizumab: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Vitamin K alone does not reverse life-threatening warfarin bleeding rapidly enough

Trimethoprim-sulfamethoxazole can substantially increase warfarin’s anticoagulant effect through metabolic interaction and changes in vitamin K availability.

Why the other options are less appropriate

• A. Saline nasal spray: is less consistent with the full clinical context and is not the single best answer.
• B. Calcium carbonate: is less consistent with the full clinical context and is not the single best answer.
• C. Psyllium: is less consistent with the full clinical context and is not the single best answer.
• D. Topical moisturizer: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Vitamin K alone does not reverse life-threatening warfarin bleeding rapidly enough

Plasma can replace coagulation factors but requires larger volumes and generally corrects the INR less rapidly than four-factor PCC.

Why the other options are less appropriate

• A. As the preferred treatment for every minor bruise: is less consistent with the full clinical context and is not the single best answer.
• C. Instead of vitamin K in all cases: is less consistent with the full clinical context and is not the single best answer.
• D. Only when the INR is normal: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. To reverse apixaban specifically: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Vitamin K alone does not reverse life-threatening warfarin bleeding rapidly enough

Known massive long-acting insulin exposure with profound, recurrent hypoglycemia and hypokalemia establishes the diagnosis.

Why the other options are less appropriate

• A. Sulfonylurea toxicity: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Diabetic ketoacidosis: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Hyperosmolar hyperglycemic state: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Acute adrenal crisis: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not stop dextrose after a single normal glucose measurement

A dextrose bolus treats the immediate neuroglycopenia. A continuous glucose infusion may be required for prolonged periods because large subcutaneous insulin depots can continue releasing insulin.

Why the other options are less appropriate

• A. Additional insulin: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Octreotide as the sole treatment: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Fasting: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Metformin: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not stop dextrose after a single normal glucose measurement

Insulin activates cellular potassium uptake. Potassium may require cautious replacement, but overly aggressive replacement should be avoided because potassium can move back out of cells when insulin activity subsides.

Why the other options are less appropriate

• B. Insulin always causes irreversible hyperkalemia: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• C. Dextrose prevents potassium movement: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• D. Potassium is unrelated to insulin action: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• E. Hypoglycemia always produces hypercalcemia: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.

Clinical safety point Do not stop dextrose after a single normal glucose measurement

Octreotide suppresses endogenous pancreatic insulin secretion and is therefore useful in sulfonylurea toxicity. It does not neutralize insulin that has already been injected.

Why the other options are less appropriate

• A. It permanently blocks glucagon receptors: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• B. Octreotide contains insulin: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.
• C. Octreotide increases intestinal glucose absorption only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. It directly reverses all long-acting insulin: does not match the pathophysiologic or pharmacologic mechanism responsible for the findings.

Clinical safety point Do not stop dextrose after a single normal glucose measurement

Mucositis, diarrhea, pancytopenia, infection risk, renal dysfunction, and hepatic injury after repeated daily methotrexate dosing indicate severe toxicity.

Why the other options are less appropriate

• A. Immune thrombocytopenia only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Iron-deficiency anemia only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• D. Uncomplicated aphthous ulcers: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Acute hyperthyroidism: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point A low or undetectable serum methotrexate concentration does not reliably exclude serious toxicity after repeated low-dose exposure

Leucovorin provides reduced folate that bypasses methotrexate’s inhibition of dihydrofolate reductase and helps rescue normal cells.

Treatment should not be delayed when serious toxicity is strongly suspected.

Why the other options are less appropriate

• A. Naloxone: is less consistent with the full clinical context and is not the single best answer.
• C. Vitamin K: is less consistent with the full clinical context and is not the single best answer.
• D. Pralidoxime: is less consistent with the full clinical context and is not the single best answer.
• E. Dantrolene: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point A low or undetectable serum methotrexate concentration does not reliably exclude serious toxicity after repeated low-dose exposure

Methotrexate is substantially eliminated by the kidneys. Acute or chronic renal impairment reduces clearance and increases the risk of bone-marrow, gastrointestinal, hepatic, and systemic toxicity.

Why the other options are less appropriate

• A. Correct weekly administration: is less consistent with the full clinical context and is not the single best answer.
• B. High HDL cholesterol: is less consistent with the full clinical context and is not the single best answer.
• C. Mild seasonal allergies: is less consistent with the full clinical context and is not the single best answer.
• E. Topical moisturizer use: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point A low or undetectable serum methotrexate concentration does not reliably exclude serious toxicity after repeated low-dose exposure

Glucarpidase rapidly converts circulating methotrexate into inactive metabolites through a nonrenal pathway. It is primarily used for toxic methotrexate concentrations associated with delayed elimination and kidney injury after high-dose therapy.

Why the other options are less appropriate

• A. Cyproheptadine: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Digoxin immune Fab: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Hydroxocobalamin: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Flumazenil: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point A low or undetectable serum methotrexate concentration does not reliably exclude serious toxicity after repeated low-dose exposure

Clozapine exposure, profound neutropenia, fever, hypotension, elevated lactate, and organ dysfunction indicate severe neutropenia complicated by sepsis.

Why the other options are less appropriate

• A. Serotonin syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Uncomplicated viral pharyngitis: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Neuroleptic malignant syndrome: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Acute lithium toxicity: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Removal of an administrative REMS requirement does not mean that hematologic monitoring is unnecessary

This is a life-threatening infection emergency. Clozapine should be withheld, and broad-spectrum antimicrobial therapy, cultures, intravenous fluids, and sepsis management should begin promptly.

Why the other options are less appropriate

• A. Wait for the throat culture before treating: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• B. Continue clozapine and reassess in one month: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• C. Prescribe an herbal immune stimulant only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Discharge with acetaminophen: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Removal of an administrative REMS requirement does not mean that hematologic monitoring is unnecessary

ANC monitoring identifies patients developing clinically important neutropenia. Symptoms such as fever, sore throat, oral ulcers, or infection require immediate assessment even when routine monitoring has previously been normal.

Why the other options are less appropriate

• A. INR: is less consistent with the full clinical context and is not the single best answer.
• C. Serum lipase: is less consistent with the full clinical context and is not the single best answer.
• D. Troponin only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Serum amylase: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Removal of an administrative REMS requirement does not mean that hematologic monitoring is unnecessary

The administrative REMS requirements changed, but the underlying clinical risk did not disappear. Prescribers should continue ANC monitoring according to current prescribing information.

Why the other options are less appropriate

• B. ANC monitoring is no longer clinically important: is less consistent with the full clinical context and is not the single best answer.
• C. Clozapine cannot cause severe neutropenia: is less consistent with the full clinical context and is not the single best answer.
• D. Pharmacies must permanently retain the former REMS requirements: is less consistent with the full clinical context and is not the single best answer.
• E. Fever during clozapine therapy requires no investigation: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Removal of an administrative REMS requirement does not mean that hematologic monitoring is unnecessary

Several people developing similar neurologic and gastrointestinal symptoms in an enclosed environment with a combustion source strongly suggests carbon monoxide exposure.

Why the other options are less appropriate

• A. Viral gastroenteritis: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Opioid toxicity: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Acute bacterial meningitis: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Food allergy: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not use a normal conventional pulse-oximetry reading to rule out carbon monoxide poisoning

Standard pulse oximeters may display a falsely reassuring saturation because they cannot accurately differentiate carboxyhemoglobin from oxyhemoglobin.

Why the other options are less appropriate

• B. Carbon monoxide affects only plasma oxygen: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• C. Pulse oximetry directly measures tissue oxygen extraction: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Carbon monoxide always produces a saturation below 80%: does not explain the complete pattern of history, examination findings, and available investigations.
• E. Pulse oximetry becomes inaccurate only during fever: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.

Clinical safety point Do not use a normal conventional pulse-oximetry reading to rule out carbon monoxide poisoning

The patient should be removed from the exposure and treated immediately with high-concentration oxygen while airway, breathing, circulation, neurologic status, ECG, and cardiac biomarkers are assessed.

Why the other options are less appropriate

• A. Naloxone: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Oral iron: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Sodium bicarbonate only: is incomplete or potentially unsafe because it could delay definitive assessment or treatment.
• E. Fluid restriction: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not use a normal conventional pulse-oximetry reading to rule out carbon monoxide poisoning

Neurologic impairment, loss of consciousness, cardiac involvement, severe acidosis, pregnancy, or substantially elevated carboxyhemoglobin may support hyperbaric consultation. The clinical condition is more important than a single delayed concentration.

Why the other options are less appropriate

• A. Mild headache that resolves immediately: is less consistent with the full clinical context and is not the single best answer.
• C. Normal neurologic examination: is less consistent with the full clinical context and is not the single best answer.
• D. Isolated rhinorrhea: is less consistent with the full clinical context and is not the single best answer.
• E. Normal carboxyhemoglobin after prolonged oxygen treatment: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not use a normal conventional pulse-oximetry reading to rule out carbon monoxide poisoning

Persistent cyanosis, an oxygen saturation near 85%, chocolate-coloured blood, normal dissolved arterial oxygen, and oxidizing medication exposure indicate methemoglobinemia.

Why the other options are less appropriate

• A. Pulmonary embolism: does not explain the complete pattern of history, examination findings, and available investigations.
• B. Acute asthma: does not explain the complete pattern of history, examination findings, and available investigations.
• C. Carbon monoxide poisoning: does not explain the complete pattern of history, examination findings, and available investigations.
• D. Cyanide poisoning: does not explain the complete pattern of history, examination findings, and available investigations.

Clinical safety point Do not repeatedly increase oxygen alone without considering dyshemoglobinemia when cyanosis and saturation remain unexplained

Methylene blue accelerates the reduction of methemoglobin to functional hemoglobin and is first-line therapy for life-threatening acquired methemoglobinemia.

Why the other options are less appropriate

• A. Hydroxocobalamin: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• B. Naloxone: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• D. Fomepizole: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.
• E. Vitamin K: does not address the highest-priority clinical decision and may delay more appropriate assessment or treatment.

Clinical safety point Do not repeatedly increase oxygen alone without considering dyshemoglobinemia when cyanosis and saturation remain unexplained

Methylene blue depends on NADPH generated through the G6PD pathway. In significant G6PD deficiency, treatment may be ineffective and can aggravate hemolysis.

Why the other options are less appropriate

• A. Osteoarthritis: is less consistent with the full clinical context and is not the single best answer.
• B. Iron deficiency: is less consistent with the full clinical context and is not the single best answer.
• C. Hypothyroidism: is less consistent with the full clinical context and is not the single best answer.
• D. Seasonal allergic rhinitis: is less consistent with the full clinical context and is not the single best answer.

Clinical safety point Do not repeatedly increase oxygen alone without considering dyshemoglobinemia when cyanosis and saturation remain unexplained